Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.

Results with active treatment from that study failed to reach statistical significance vs placebo for the job loss/imminent job loss end point at week 56, which may have been because of the considerable dropout rates observed.

also in 6,035 other papers